DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease
NCT05685394
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
80
Enrollment
OTHER
Sponsor class
Conditions
End-stage Kidney Disease
Interventions
DRUG:
Dapagliflozin
Sponsor
University of Campinas, Brazil